weigh loss Cagrilintide peptide;Cagrilintide 5mg 10mg 15mg;Kagliptin;safe delivery ready stock

1.Description

Cagrilintide, with research codes AM833 / AT42613 and CAS number 1415456‑99‑3, is a long‑acting synthetic amylin analogue developed by the Danish pharmaceutical company Novo Nordisk. It belongs to the peptide drugs of amylin receptor/calcitonin receptor agonists.

2.Function

(1) Central appetite‑suppressing effect and enhanced satiety
Cagrilintide activates amylin receptors in the area postrema and hypothalamus of the central nervous system, directly regulating the appetite center to reduce hunger and increase satiety, thereby lowering spontaneous food intake. This is its core mechanism of action.
(2)Delayed gastric emptying
It slows gastric emptying, prolongs post‑prandial satiety duration, reduces eating frequency and single‑meal food intake, and mitigates post‑prandial blood glucose fluctuations.
(3) Significant body‑weight reduction

3.Application fields

1. Obesity and Weight Management (Core Indication)
The primary application of cagrilintide (especially the CagriSema combination) is long‑term weight management in adults with obesity or overweight accompanied by weight‑related comorbidities. Trials within the REDEFINE clinical program have verified its remarkable weight‑loss efficacy of over 20%, placing it among the first‑line anti‑obesity medications currently available.

2. Type 2 Diabetes Mellitus
Trials from the REIMAGINE clinical program have demonstrated that CagriSema delivers dual benefits of significant glycemic reduction (HbA1c lowering) and weight loss in patients with type 2 diabetes mellitus, outperforming semaglutide monotherapy. It is suitable for patients with type 2 diabetes mellitus who require concurrent glycemic and weight control.

3. Metabolic Syndrome
By reducing body weight, improving insulin sensitivity, and regulating blood glucose and blood lipids, cagrilintide can ameliorate multiple markers of metabolic syndrome, including waist circumference, blood pressure, triglycerides and HDL‑cholesterol.

4.Application as a Research Reagent
Prior to official approval, cagrilintide (CAS: 1415456‑99‑3) has been widely utilized as a research‑grade peptide in:
Basic research on metabolic diseases (obesity, diabetes mellitus)
Research on amylin receptor signaling pathways
Studies on appetite regulation and energy metabolism mechanisms
Peptide drug development and structure‑activity relationship (SAR) research
Pre‑clinical research on combination therapy with GLP‑1 receptor agonists

4. Packing & Shipping

Generally, the Cagrilintide  will be packed in two plastic bags and one foil bag, and then a fiber drum for 25kg.